Cytokine gene polymorphisms: Association with psoriatic arthritis susceptibility and severity

Arthritis and Rheumatism

Volumn 48, Issue 5, 2003, Pages 1408-1413

  Balding, Joanna ^a   Kane, David ^b   Livingstone, Wendy ^c   Mynett Johnson, Lesley ^a   Bresnihan, Barry ^b   Smith, Owen ^c   FitzGerald, Oliver ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE EROSION; CHILD; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PSORIATIC ARTHRITIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ARTHRITIS, PSORIATIC; ARTHROGRAPHY; CHILD; CHILD, PRESCHOOL; CYTOKINES; DNA; DNA PRIMERS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; JOINTS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEVERITY OF ILLNESS INDEX;

EID: 0037652341     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10935     Document Type: Article

References (15)

1. Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs 2000;9:1511-22.
2. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991;30:245-50.
3. Veale D, Yanni G, Rogers S, Barnes L, Bresnihan B, Fitzgerald O. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 1993;36:893-900.
4. Elkayam O, Yaron I, Shirazi I, Yaron M, Caspi D. Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. Rheumatol Int 2000;19:101-5.
5. Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997;24:518-23.
6. Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB. Macrophage-derived cytokine and nuclear factor κB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000;43:1244-56.
7. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
8. Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis 1973;32:181-201.
9. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1999;1:3-19.
10. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
11. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
12. Woodrow JC, Ilchysyn A. HLA antigens in psoriasis and psoriatic arthritis. J Med Genet 1985;22:492-5.
13. Spadaro A, Taccari E, Riccieri V, Sensi F, Sili Scavalli A, Zoppini A. Interleukin-6 and soluble interleukin-2-receptor in psoriatic arthritis: correlations with clinical and laboratory parameters. Clin Exp Rheumatol 1996;14:413-6.
14. Nordahl S, Alstergren P, Eliasson S, Kopp S. Interleukin-1beta in plasma and synovial fluid in relation to radiographic changes in arthritic temporomandibular joints. Eur J Oral Sci 1998;106:559-63.
15. McInnes IB, Gracie JA, Leung BP, Wei XQ, Liew FY. Interleukin 18: a pleiotropic participant in chronic inflammation. Immunol Today 2000;21:312-5.